Clinical and Molecular Biological Data Collection and Analysis in Patients With TBI

Condition(s) studied

Investigational drug(s) / intervention(s)

No intervention: patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected

Study summary

Clinical evaluation is crucial in the clinical diagnosis, treatment, and prognosis prediction in patients with traumatic brain injury (TBI). However, the existing evaluation systems are not perfect, because many factors are not taken into account, for example, there is a lack of molecular diagnostic criteria for evaluating patients with TBI. We attempt to collect the patient's clinical data and combine it with neuroimaging, as well as molecular biomarkers generated by single-cell sequencing to assess their neurological status and outcome. The clinical and molecular data collection and analysis will be helpful to evaluate the patient's neurological condition and predict the patient's outcome more accurately.

Eligibility

Primary outcome measure(s)

• Accurate assessment of patients' neurological condition — 2022.09-2023.12
  Using a regression model to explore the relationship between a patient's neurological condition and clinical and molecular biological data

Trial sites (1)

More Shanghai 6th People's Hospital trials in China

Other trials for the same condition